间充质干细胞来源外泌体改善心肌纤维化的研究进展  

Improving Myocardial Fibrosis by Exosome Derived from Mesenchymal Stem Cell

作　　者：杨珂欣 李星辉[1,2] 肖晨朦 姚晓涛 林萌 蔡佳 YANG Kexin;LI Xinghui;XIAO Chenmeng;YAO Xiaotao;LIN Meng;CAI Jia(Lanzhou University,Lanzhou 730000,Gansu,China;Department of Cardiology,Gansu Provincial Hospital,Lanzhou 730000,Gansu,China;Gansu University of Chinese Medicine,Lanzhou 730000,Gansu,China;Ningxia Medical University,Yinchuan 750000,Ningxia,China)

机构地区：[1]兰州大学,甘肃兰州730000 [2]甘肃省人民医院心内一科,甘肃兰州730000 [3]甘肃省中医药大学,甘肃兰州730000 [4]宁夏医科大学,宁夏银川750000

出　　处：《心血管病学进展》2022年第12期1123-1126,共4页Advances in Cardiovascular Diseases

摘　　要：心血管疾病具有全球高发病率和高病死率。心肌纤维化影响心血管疾病患者临床预后。间充质干细胞通过旁分泌作用减轻心肌纤维化。间充质干细胞来源外泌体能克服干细胞疗法免疫排斥和致瘤性等缺陷,通过内部的miRNA传递信息并调控靶细胞,参与调节心肌纤维化的病理形成过程,有望指导疾病的诊断、治疗及预后。现对间充质干细胞来源外泌体及其携带的miRNA在心肌纤维化过程中的最新研究进展进行综述,揭示其在心血管疾病中的潜在作用。Cardiovascular disease has a high global morbidity and mortality rate.Myocardial fibrosis affects the clinical prognosis of patients with cardiovascular disease.Mesenchymal stem cell alleviate myocardial fibrosis through paracrine effects.Mesenchymal stem cell-derived exosome can overcome the defects of stem cell therapy such as immune rejection and tumorigenicity,and regulate the pathogenesis of myocardial fibrosis by transmitting information and regulating target cells through internal miRNA,which is expected to guide the diagnosis,treatment and prognosis of the disease.In this paper,we have reviewed mesenchymal stem cell-derived exosome and the miRNA which carried in the process of myocardial fibrosis to reveal their potential roles in cardiovascular disease.

关 键 词：心肌纤维化 间充质干细胞 外泌体 miRNA 

分 类 号：R54[医药卫生—心血管疾病]